The latest price target for Aquestive Therapeutics (NASDAQ:AQST) was reported by HC Wainwright & Co. on March 10, 2025. The analyst firm set a price target for $10.00 expecting AQST to rise to within 12 months (a possible 211.53% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Aquestive Therapeutics (NASDAQ:AQST) was provided by HC Wainwright & Co., and Aquestive Therapeutics reiterated their buy rating.

The last upgrade for Aquestive Therapeutics Inc happened on March 9, 2023 when Wedbush raised their price target to $4. Wedbush previously had a neutral for Aquestive Therapeutics Inc.

There is no last downgrade for Aquestive Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aquestive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aquestive Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.

While ratings are subjective and will change, the latest Aquestive Therapeutics (AQST) rating was a reiterated with a price target of $10.00 to $10.00. The current price Aquestive Therapeutics (AQST) is trading at is $3.21, which is out of the analyst’s predicted range.